A randomized, multi-center phase II trial to assess the efficacy of 5-azacytidine added to standard primary therapy in elderly patients with newly diagnosed AML

Beteiligte Wissenschaftler:
Akad. Rat Dr. Dipl.-Stat. J. Gerß
Dipl.-Stat. M. Eveslage
Dr. Dipl.-Stat. M. Borowski

Studienleitung:
Prof. Dr. med. C. Müller-Tidow